Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 3Pancreatic Neoplasms 2Neoplasm Metastasis 2Lung Neoplasms 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Penile Neoplasms 1Oropharyngeal Neoplasms 1Mouth Neoplasms 1Mesothelioma, Malignant 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Carcinoma, Neuroendocrine 1Carcinoma 1Ataxia Telangiectasia 1

Interventions

pembrolizumab 1BAY 1895344 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Ataxia Telangiectasia × BAY 1895344 × Clear all
NCT04095273 2024-04-02

Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug

Bayer

Phase 1 Completed
56 enrolled

Ataxia Telangiectasia, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡